BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
See today's BioWorld
Home
» Tragara Pays $112M to Jointly Develop S*BIO Compound
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Tragara Pays $112M to Jointly Develop S*BIO Compound
Jan. 22, 2009
By
Catherine Hollingsworth
No Comments
Singapore-based S*BIO Pte. Ltd. has joined with San Diego-based Tragara Pharmaceuticals Inc. to develop a potential treatment for blood cancer and possibly solid tumors, in a deal worth up to $112.5 million. (BioWorld Today)
BioWorld